SCHEMBL15550324

SCHEMBL15550324

CCN(C(=O)c1ccoc1)c1nc2ccccc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C19 P33261 1/20 0.50
POLB P06746 2/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
RAB9A P51151 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
MCL1 Q07820 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 3/20 0.39
PKM P14618 1/20 0.39
KLF5 Q13887 1/20 0.39
KMT2A Q03164 2/20 0.39
DDAH1 O94760 1/20 0.38
KDM4E B2RXH2 2/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15550992 0.86 LMNA (0.56) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL15550310 0.82 LMNA (0.52) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL9162960 0.79 LMNA (0.60) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL4888617 0.76 LMNA (0.56) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL1231980 0.71 CYP1A2 (0.50) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL6955715 0.69 LMNA (0.96) LMNACYP1A2CYP2D6CYP2C19BCHE
SCHEMBL15550989 0.68 LMNA (0.50) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL9275387 0.68 ALDH1A1 (0.50) LMNACYP1A2CYP2D6CYP2C19POLB
SCHEMBL11782333 0.68 ALDH1A1 (0.50) LMNACYP1A2CYP2D6CYP2C19BCHE
SCHEMBL8160319 0.68 LMNA (0.47) LMNACYP1A2CYP2D6CYP2C19POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9550737-B2 TNF -α modulating benzimidazoles UCB BIOPHARMA SPRL (BE) 2017-01-24 US disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA LMNA 3064/4885CYP1A2 1933/4885CYP2D6 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.